Meldola

• A randomized, double-blind, Phase III Study of AZD9833 plus CDK4/6 inhibitor in patients with metastatic breast cancer with detectable ESR1 … Ended recruitment
  2023-503990-39-00 5 2021-09-30 Estrogen Receptor-Positive, HER-2 negative Advanced Breast Cancer
• MagnetisMM-5: A Phase 3 Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dex … Ended recruitment
  2023-509208-14-00 5 2021-09-28 MULTIPLE MYELOMA
• A trial to assess efficacy and safety of octreotide subcutaneous depot in patients with GEP-NET Ended recruitment
  2023-508723-12-00 5 2021-09-27 gastroenteropancreatic neuroendocrine tumors
• Phase 3 Randomized Study of Talazoparib with Enzalutamide in Men with DDR Gene Mutated mCSPC Ended recruitment
  2024-510809-28-00 5 2021-09-27 Metastatic Castration-sensitive Prostate Cancer
• The study aims to verify the greater efficacy of the treatment of Acute Lymphoblastic Leukemia Ph + through the combination of Ponatinib and … Ended recruitment
  2023-508968-30-00 5 2021-09-08 Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
• RECHALLENGE WITH PEGYLATED LIPOSOMAL DOXORUBICIN ADDED TO TRABECTEDIN IN RECURRENT OVARIAN CANCER: A MULTICENTER, PROSPECTIVE TRIAL.(REPRAB … Ended recruitment
  2024-518847-40-00 4 2021-07-16 recurrent ovarian cancer
• Isatuximab in combination with belantamab mafodotin and dexamethasone in RRMM. Ended recruitment
  2024-514989-40-00 9 2021-05-17 Cancer
• Trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to standard therapy versus standard therapy in patients … Ended recruitment
  2022-500237-92-00 5 2021-04-23 Newly-diagnosed high-intermediate and high-risk diffuse large B-cell l
• Phase 3 Study of Belzutifan in Combination With Lenvatinib Versus Cabozantinib for Treatment of RCC Ended recruitment
  2024-510620-39-00 5 2021-04-19 Advanced RCC with clear cell component
• A study comparing current available therapies with imetelstat for the treatment of intermediate-2 or high-risk MF who are not responding to … Ended recruitment
  2023-509120-17-00 5 2021-04-12 Myelofibrosis
• A Phase 3 Randomized Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Patients with Relapsed or Refracto … Ended recruitment
  2023-503916-33-00 5 2021-03-24 Diffuse Large B-Cell Lymphoma (DLBCL)
• Prephase treatment with prednisone +/- Vitamin D supplementation followed by immunochemotherapy in Elderly patients with Diffuse Large B-Cel … Ended recruitment
  2024-511637-35-00 5 2021-03-23 Elderly patients with Diffuse Large B-Cell Lymphoma (DLBCL)
• MITO 25.1: A randomized, molecular driven phase II trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucapar … Ended recruitment
  2024-516632-99-00 4 2021-03-17 Advanced (stage III B-C-IV) ovarian, primary peritoneal and Fallopian
• An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cance … Ended recruitment
  2022-502600-79-00 4 2021-03-16 Endometrial cancer
• A Study to Evaluate Effects of Atezolizumab (anti-PD-L1 antibody) as an Adjuvant Therapy in Patients with High-Risk Muscle-invasive Bladder … Ended recruitment
  2022-502705-15-00 5 2021-03-08 High-risk muscle-invasive bladder cancer
• A clinical study to assess the effectiveness and safety of LOXO-305 compared to standard of care treatment chosen by the Investigator in pat … Ended recruitment
  2023-507695-52-00 5 2021-03-05 Mantle cell lymphoma
• A study to evaluate the benefit and safety of Luspatercept (ACE-536) in adults with myeloproliferative neoplasm-associated myelofibrosis on … Ended recruitment
  2023-507890-17-00 5 2021-02-22 Anemia associated with myeloproliferative neoplasm (MPN)-associated my
• A Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in R/R DLBCL Ended recruitment
  2023-504830-23-00 5 2020-12-16 B-cell Lymphoma
• A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Pa … Ended recruitment
  2023-506911-16-00 5 2020-12-04 ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTAT
• Study of the Safety and Efficacy of KRT-232 Combined with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post–Polycythemia Vera M … Ended recruitment
  2024-514468-26-00 9 2020-12-04 Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), O
• Comparison of two strategies that use the same drugs but with inverted sequence for the treatment of patients with metastatic colorectal can … Ended recruitment
  2024-513296-41-00 4 2020-12-03 Colorectal cancer spread at distance, RAS BRAF wild type pretreatted
• A Combination of Acalabrutinib with R-CHOP in Subjects with previously untreated non-GCB DLBCL Ended recruitment
  2023-509358-72-00 5 2020-11-23 Diffuse large B-cell lymphoma
• Safety and Efficacy Study of Epcoritamab in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome Ended recruitment
  2023-504828-25-00 9 2020-11-16 Chronic Lymphocytic Leukemia
• Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) Ended recruitment
  2023-504805-35-00 9 2020-10-22 Lymphoma of B-cell origin

Showing 313–336 of 447 trials